spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed

Ypsomed AG


Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.

Teva has announced the launch of AJOVY® in an autoinjector device for the German market in March 2020. AJOVY® (fremanezumab-vfrm), a humanised monoclonal antibody, is the first and only anti-CGRP treatment for the prevention of migraine with monthly and quarterly dosing options. According to the World Health Organisation, at least one in seven adults is affected by migraine worldwide. To date, Teva has marketed AJOVY® in a standard syringe. With the launch of the drug in an autoinjector, Teva now offers AJOVY® in a format, which is more convenient for patients.

The YpsoMate 2.25 auto-injector is based on the same platform as the YpsoMate with 1.0 ml fill volume, but is assembled with a syringe with 2.25 ml fill volume. Due to the higher fill volume, the YpsoMate 2.25 is also suitable for drugs that need to be injected less frequently but in higher volumes. Ypsomed manufactures its YpsoMate 2.25 on a fully automated production line at its Solothurn site in Switzerland.

“For us, the cooperation with Teva is yet another important milestone for our YpsoMate autoinjector platforms. It is not only the second realised YpsoMate project with Teva, but also the first commercial market launch for the YpsoMate 2.25 large volume autoinjector. We see a growing need for injection devices for home use to increase quality of life for patients,” comments Ulrike Bauer, Senior Vice President Ypsomed Delivery Systems.
phone +41 34 424 4111
email Ian.Thompson@ypsomed.com
web www.ypsomed.com/
email Brunnmattstrasse 6, 3401 Burgdorf, Switzerland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

SONOTEC® launches industrial clamp-on flow meter for plastic tubes and pipes for the use in hazardous areas of Zone 1 according to ATEX/IECEx

The new SEMIFLOW Ex1 Set opens a new product category of intrinsically safe ultrasonic flow sensors with control gear for non-contact liquid flow measurement on small and midsize rigid plastic tubes to ensure safe operation in hazardous areas. SEMIFLOW CO.66 PI Ex1 sensors are protected against explosion hazard by gases, vapors, and liquids according to the gas group IIB. The device protection level (EPL) is "Gb" for the use in Zone 1 according to ATEX/IECEx.
More info >>


White Papers

Nasal Drug Delivery with a Focus on Chronic Rhino-Sinusitis

Aptar Pharma

Aptar Pharma have hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs.
More info >>

Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement